Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Clinical trial NCT03397706 · COMPLETED
Trial details
- NCT number
- NCT03397706
- Sponsor
- Viracta Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-29
- Primary completion
- 2023-04-01
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.